Carl C Askren, MD
Plastic and Reconstructive Surgery · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 42 years
- Emory University School of Medicine, 1984
Offices
2 locations · Central Calif Ent Medical Group · Aesthetic Plastic Surgery Associates
Looking this up.
Hospitals listed: Saint Agnes Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Askren’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence G60139 · Current
Licensed to practise in California · since 1987 · expires 2026-11-30 · Emory University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Plastic Surgery - Plastic Surgery
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Saint Agnes Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.312, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.141, Oct 2024 – Sep 2025
See every measure and the patient survey for Saint Agnes Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.312 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.141 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.18 to 1.94) · 2,342 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 197.82 (152.64 to 243.01) · 103 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 300 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 768 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.8 · 969 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 304 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 4,305 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.06 to 0.42) · 11,641 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.07 to 0.43) · 12,213 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.76 (2.91 to 6.61) · 2,466 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.09 (0 to 2.49) · 864 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.61 (0.26 to 2.96) · 2,362 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.1 (5.39 to 14.81) · 900 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.4 (1.2 to 7.59) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.84 (0.41 to 3.27) · 541 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.67 (0.14 to 1.19) · 9,626 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 58 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.835 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.182 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.004 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 412 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.6 · 1,002 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 28.8 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.5 · 894 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.8 · 981 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 1,061 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13.4 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 412 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.6 to 15.9) · 1,324 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 863 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 32% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$24,403
Medicare paid this office $24,403 for 93 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit | 67 | $3,341 | $42 |
Procedures Medicare counted
| Mastectomy | 1-10 | None |
| Melanoma (skin cancer) excision | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Implantation of biologic implant to soft tissue | 13 | – | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
93 Original Medicare patients in 2024. Average age 72 · Health risk score 0.89. At or below the middle of the specialty; the typical plastic and reconstructive surgery clinician is at 1.21.
Conditions among them: Cancer 75% · High blood pressure 65% · Coronary heart disease 33% · Depression 31% · Diabetes 18% · Chronic kidney disease 16% · Atrial fibrillation 15%.
The office billed $87,370, Medicare allowed $31,297 and paid $24,403; for 146 services of 26 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 93 | 146 | 72 | 0.89 | $87,370 | $24,403 |
| 2023 | 110 | 202 | 72 | 0.78 | $135,696 | $38,608 |
| 2022 | 108 | 200 | 72 | 0.69 | $129,882 | $33,384 |
| 2021 | 87 | 177 | 72 | 0.70 | $91,024 | $24,806 |
| 2020 | 89 | 195 | 71 | 0.84 | $167,577 | $45,285 |
| 2019 | 100 | 257 | 71 | 0.79 | $209,468 | $58,761 |
| 2018 | 80 | 196 | 71 | 0.78 | $246,860 | $64,882 |
| 2017 | 74 | 153 | 72 | 0.82 | $160,126 | $42,966 |
| 2016 | 73 | 161 | 71 | 0.96 | $142,984 | $38,003 |
| 2015 | 89 | 224 | 70 | 0.90 | $221,750 | $64,037 |
| 2014 | 77 | 190 | 69 | 0.84 | $206,630 | $55,006 |
| 2013 | 63 | 183 | 71 | 0.88 | $218,071 | $53,057 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Short return visit | 86 | $4,215 | $39 |
2022: 2 services
| Short return visit | 81 | $4,431 | $40 |
| Short return visit (20+ min) | 11 | $816 | $74 |
2021: 2 services
| Short return visit | 55 | $2,948 | $40 |
| Short return visit (20+ min) | 12 | $1,065 | $71 |
2020: 2 services
| Short return visit | 59 | $2,387 | $32 |
| Short return visit (20+ min) | 11 | $599 | $50 |
2019: 4 services
| Implantation of biologic implant to soft tissue | 13 | $2,448 | $188 |
| New patient visit (45+ min) | 17 | $2,218 | $130 |
| Short return visit (20+ min) | 38 | $2,186 | $48 |
| Short return visit | 47 | $1,787 | $35 |
2018: 4 services
| Reconstruction of breast using tissue expander | 12 | $13,878 | $1,157 |
| New patient visit (45+ min) | 29 | $3,600 | $124 |
| Implantation of biologic implant to soft tissue | 16 | $2,471 | $154 |
| Short return visit (20+ min) | 24 | $1,420 | $55 |
2017: 2 services
| New patient visit (45+ min) | 17 | $2,164 | $127 |
| Short return visit | 36 | $1,134 | $25 |
2016: 3 services
| Short return visit | 37 | $1,654 | $30 |
| New patient visit (45+ min) | 12 | $1,520 | $127 |
| Short return visit (20+ min) | 16 | $903 | $53 |
2015: 7 services
| Reconstruction of breast using tissue expander | 14 | $18,195 | $1,300 |
| Implantable breast prosthesis, silicone or equal | 12 | $8,649 | $509 |
| Placement of implant on separate day of breast reconstruction | 12 | $8,538 | $712 |
| Implantation of biologic implant to soft tissue | 18 | $3,290 | $183 |
| Short return visit | 51 | $2,398 | $32 |
| New patient visit (45+ min) | 17 | $2,232 | $131 |
| Short return visit (20+ min) | 11 | $468 | $43 |
2014: 4 services
| Reconstruction of breast using tissue expander | 12 | $15,117 | $1,260 |
| Implantation of biologic implant to soft tissue | 13 | $2,410 | $172 |
| New patient visit (45+ min) | 18 | $2,303 | $128 |
| Short return visit | 38 | $1,951 | $35 |
2013: 4 services
| Implantation of biologic implant to soft tissue | 13 | $2,699 | $193 |
| New patient visit (45+ min) | 19 | $2,325 | $122 |
| Short return visit (20+ min) | 17 | $1,099 | $50 |
| Short return visit | 24 | $1,091 | $34 |
Drugs they prescribed that Part D paid
$1,301
Pharmacies billed $1,301 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 26% of their Part D prescriptions (33 of 126) in 2024. At or below the middle of the specialty; the typical plastic and reconstructive surgery clinician is at 28%. Surgeons prescribe little besides pain medicine after an operation, so their opioid share runs high.
126 generic and 0 brand-name prescriptions · $1,301 in drug cost · 39 antibiotic prescriptions to 29 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Cephalexin | 25 | $522 | $16 |
| Celecoxib | 11 | $266 | $22 |
| Hydrocodone-Acetaminophen | 23 | $163 | $6 |
| Ondansetron Odt | 25 | $138 | $5 |
Year by year
| 2024 | 126 | 31 | 26% (33) | 0% | $1,301 |
| 2023 | 170 | 41 | 23% (39) | None | $2,223 |
| 2022 | 93 | 28 | 29% (27) | 0% | $1,174 |
| 2021 | 104 | 34 | 26% (27) | None | $913 |
| 2020 | 122 | 41 | 25% (31) | None | $1,289 |
| 2019 | 150 | 57 | 25% (38) | None | $1,048 |
| 2018 | 179 | 49 | 26% (46) | None | $1,620 |
| 2017 | 148 | 52 | 23% (34) | None | $2,307 |
| 2016 | 84 | 34 | 31% (26) | 0% | $801 |
| 2015 | 139 | 44 | 27% (38) | None | $1,644 |
| 2014 | 135 | 45 | 28% (38) | None | $2,042 |
| 2013 | 68 | 22 | 32% (22) | None | $1,341 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Celecoxib | 31 | $1,106 | $36 |
| Cephalexin | 41 | $278 | $7 |
| Ondansetron Odt | 30 | $192 | $6 |
| Hydrocodone-Acetaminophen | 21 | $116 | $6 |
| Tramadol | 15 | $56 | $4 |
2022: 4 drugs
| Celecoxib | 15 | $732 | $49 |
| Hydrocodone-Acetaminophen | 23 | $120 | $5 |
| Cephalexin | 21 | $107 | $5 |
| Ondansetron Odt | 12 | $98 | $8 |
2021: 4 drugs
| Celecoxib | 17 | $383 | $23 |
| Hydrocodone-Acetaminophen | 26 | $132 | $5 |
| Cephalexin | 27 | $123 | $5 |
| Ondansetron Odt | 17 | $122 | $7 |
2020: 3 drugs
| Ondansetron Odt | 34 | $328 | $10 |
| Hydrocodone-Acetaminophen | 30 | $135 | $4 |
| Cephalexin | 32 | $109 | $3 |
2019: 4 drugs
| Hydrocodone-Acetaminophen | 34 | $207 | $6 |
| Ondansetron Odt | 32 | $199 | $6 |
| Cephalexin | 42 | $146 | $3 |
| Ciprofloxacin | 12 | $74 | $6 |
2018: 4 drugs
| Hydrocodone-Acetaminophen | 40 | $355 | $9 |
| Cephalexin | 60 | $275 | $5 |
| Ondansetron Odt | 32 | $204 | $6 |
| Baclofen | 13 | $80 | $6 |
2017: 3 drugs
| Hydrocodone-Acetaminophen | 33 | $331 | $10 |
| Cephalexin | 48 | $298 | $6 |
| Ondansetron Odt | 25 | $152 | $6 |
2016: 3 drugs
| Hydrocodone-Acetaminophen | 23 | $287 | $12 |
| Ondansetron Odt | 15 | $118 | $8 |
| Cephalexin | 25 | $110 | $4 |
2015: 3 drugs
| Hydrocodone-Acetaminophen | 28 | $387 | $14 |
| Ondansetron Odt | 20 | $157 | $8 |
| Cephalexin | 37 | $145 | $4 |
2014: 3 drugs
| Hydrocodone-Acetaminophen | 20 | $552 | $28 |
| Ondansetron Odt | 21 | $191 | $9 |
| Cephalexin | 34 | $151 | $4 |
2013: 2 drugs
| Hydrocodone-Acetaminophen | 19 | $105 | $6 |
| Cephalexin | 17 | $101 | $6 |
Money from drug and device companies
$1,142 in 2025
| 2025 | 6 | 20 | None | $1,142 |
| 2024 | 5 | 36 | None | $2,006 |
| 2023 | 5 | 42 | None | $2,266 |
| 2022 | 7 | 46 | None | $3,468 |
| 2021 | 6 | 50 | None | $3,358 |
| 2020 | 6 | 40 | None | $2,114 |
| 2019 | 9 | 77 | $1,500 | $6,760 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mentor Worldwide | Mentor Memorygel Resterilizable Gel Sizer | $543 | 11 payments
|
| Galderma Laboratories L.P. | None | $215 | 2 payments
|
| Abbvie | Botox | $190 | 4 payments
|
| Musculoskeletal Transplant Foundation | None | $97 | 1 payment
|
| TELA Bio | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) | $75 | 1 payment
|
| Revance Therapeutics | Daxxify | $23 | 1 payment
|
See all 20 published payments
| Revance Therapeutics | Meals · 2025-12-19 | Daxxify | $23 |
| Mentor Worldwide | Meals · 2025-12-05 | Mentor Memorygel Resterilizable Gel Sizer | $117 |
| Galderma Laboratories L.P. | Meals · 2025-12-02 | None | $125 |
| Mentor Worldwide | Meals · 2025-10-29 | Mentor Memorygel Resterilizable Gel Sizer | $25 |
| Abbvie | Meals · 2025-10-10 | Natrelle Saline-Filled Breast Implants | $31 |
| Mentor Worldwide | Meals · 2025-09-30 | Mentor Memorygel Resterilizable Gel Sizer | $11 |
| Mentor Worldwide | Meals · 2025-08-26 | Mentor Memorygel Resterilizable Gel Sizer | $35 |
| Abbvie | Meals · 2025-08-19 | Botox | $121 |
| Musculoskeletal Transplant Foundation | Meals · 2025-07-02 | None | $97 |
| Abbvie | Meals · 2025-06-25 | Botox | $9 |
| Mentor Worldwide | Meals · 2025-06-19 | Mentor Memorygel Resterilizable Gel Sizer | $27 |
| TELA Bio | Meals · 2025-05-02 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) | $75 |
| Mentor Worldwide | Meals · 2025-05-01 | Mentor Memorygel Resterilizable Gel Sizer | $43 |
| Mentor Worldwide | Meals · 2025-04-22 | Mentor Memorygel Resterilizable Gel Sizer | $12 |
| Galderma Laboratories L.P. | Meals · 2025-03-04 | None | $90 |
| Mentor Worldwide | Meals · 2025-02-25 | Mentor Memorygel Resterilizable Gel Sizer | $134 |
| Mentor Worldwide | Meals · 2025-02-19 | Mentor Memorygel Resterilizable Gel Sizer | $111 |
| Mentor Worldwide | Meals · 2025-02-11 | Mentor Memorygel Resterilizable Gel Sizer | $15 |
| Abbvie | Meals · 2025-02-11 | Alloderm | $29 |
| Mentor Worldwide | Meals · 2025-01-28 | Mentor Memorygel Resterilizable Gel Sizer | $15 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,006
| Musculoskeletal Transplant Foundation | None | $989 | 7 payments
|
| TELA Bio | Ovitex 2s | $410 | 7 payments
|
| Mentor Worldwide | Mentor Memorygel Resterilizable Gel Sizer | $387 | 11 payments
|
| Abbvie | Natrelle Saline-Filled Breast Implants | $191 | 10 payments
|
| Integra LifeSciences | Omnigraft | $30 | 1 payment
|
2023: $2,266
| Mentor Worldwide | Mentor Memorygel Resterilizable Gel Sizer | $874 | 17 payments
|
| Musculoskeletal Transplant Foundation | None | $527 | 7 payments
|
| TELA Bio | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) | $438 | 6 payments
|
| AbbVie | Natrelle Saline-Filled Breast Implants | $327 | 11 payments
|
| Rti Surgical | Cortiva Allograft Dermis | $100 | 1 payment
|
2022: $3,468
| Sientra | Sientra High Strength Cohesive Silicone Gel Breast Implant | $1,233 | 9 payments
|
| TELA Bio | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) | $760 | 9 payments
|
| Mentor Worldwide | Mentor Memorygel Resterilizable Gel Sizer | $733 | 17 payments
|
| Musculoskeletal Transplant Foundation | None | $609 | 5 payments
|
| Allergan | Natrelle Saline-Filled Breast Implants | $105 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $15 | 1 payment
|
| Galderma Laboratories L.P. | None | $14 | 1 payment
|
2021: $3,358
| Sientra | Sientra High Strength Cohesive Silicone Gel Breast Implant | $1,266 | 11 payments
|
| TELA Bio | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) | $1,098 | 13 payments
|
| Mentor Worldwide | Mentor Memorygel Resterilizable Gel Sizer | $697 | 16 payments
|
| Galderma Laboratories L.P. | None | $166 | 6 payments
|
| Musculoskeletal Transplant Foundation | None | $88 | 2 payments
|
| Allergan | None | $43 | 2 payments
|
2020: $2,114
| TELA Bio | Ovitex | $588 | 9 payments
|
| Sientra | Sientra High Strength Cohesive Silicone Gel Breast Implant | $576 | 12 payments
|
| Musculoskeletal Transplant Foundation | None | $417 | 2 payments
|
| Mentor Worldwide | Memorygel Breast Implants | $327 | 8 payments
|
| Allergan | Natrelle | $194 | 8 payments
|
| Galderma Laboratories L.P. | None | $13 | 1 payment
|
2019: $6,760
| TELA Bio | Ovitex | $3,453 | 22 payments
|
| Medical Device Business Services | None | $1,437 | 6 payments
|
| Sientra | Sientra High Strength Cohesive Silicone Gel Breast Implant | $908 | 1 payment
|
| Allergan | Natrelle | $272 | 8 payments
|
| Mentor Worldwide | Mentor Cpx Family of Breast Tissue Expanders | $239 | 9 payments
|
| Galderma Laboratories L.P. | None | $185 | 11 payments
|
| Stryker | Disposables - Other | $95 | 1 payment
|
| Tepha | Galaflex | $93 | 2 payments
|
| Musculoskeletal Transplant Foundation | None | $80 | 4 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Sientra, Inc. · US Postapproval Study of Sientra Silicone Gel Breast Implants · 2020 | This clinician | $250 |
Professional record
- NPI
- 1134188097
- Licence
- CA G60139California G60139: Current · expires 2026-11-30
- Trained
- Emory University School of Medicine, 1984 · 42 years ago
- Group
- Central Calif Ent Medical Group · Aesthetic Plastic Surgery Associates
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G601390
- Taxonomy
- Federal specialty code 208200000X (208200000X)
- Mailing address
- 7501 N Fresno St Ste 104, Fresno, CA, 93720
- NPI first listed
- 2006-03-20
- NPI last updated
- 2026-08-20
- NPI record certified
- 2026-08-20
This is when the NPI record was last certified, not a medical board exam.